Since the link will likely expire soon, here's the actual article:
Friday April 7, 3:21 pm Eastern Time
Company Press Release
SOURCE: Hypertension Diagnostics, Inc.
Hypertension Diagnostics' CR-2000 Research System Included in the Alteon Inc. ALT-711, A.G.E. 'Crosslink Breaker', Phase II, Clinical Pharmaceutical Trial
ST. PAUL, Minn., April 7 /PRNewswire/ -- Hypertension Diagnostics, Inc. (Nasdaq: HDII; HDIIW; HDIIU), announced today that its non-invasive HDI/PulseWave(TM) CR-2000 Research CardioVascular Profiling System has been selected by Alteon Inc. (OTC Bulletin Board: ALTN - news) for inclusion in its Phase II clinical trial of its Lead A.G.E. 'Crosslink Breaker' ALT-711 (see Alteon Inc., OTCBB: ALTN, News Release for Thursday, April 06, 2000.)
``HDI's arterial elasticity indices are emerging as important and sensitive markers for arterial response as part of the development of new drugs for the pharmaceutical industry. We are excited about the opportunity to provide a cardiovascular profile system that meets Alteon's clinical requirements for obtaining information on both large and small artery elasticity,' said Dennis Sellke, HDI's CEO. ``This sale of our CR-2000 Research System, the third pharmaceutical collaboration to be announced in nine months, reinforces our innovative product attributes. Further, it highlights the new and exciting directions which cardiovascular medicine is pursuing (as well as the significant future implications for the arterial elasticity indices which HDI has pioneered and patent protected),' he continued.
The CR-2000 Research System became commercially available in late 1998 and is receiving worldwide acceptance as an important research tool. The System allows clinical researchers to readily assess changes to a research subject's arterial system during the testing of pharmaceutical compounds (or other research interventions). HDI believes that the CR-2000 Research System is the most advanced research equipment commercially available today for obtaining arterial elasticity data as well as several other cardiovascular profile parameters. It provides a quick, user-friendly and efficient approach for testing research subjects. ``The nine clinical research sites referred to in the Alteon Inc. press release are all internationally renowned for their scientific contributions. HDI is pleased to include them as users of the CR-2000 Research System, and we look forward to supporting these clinical research sites and Alteon Inc. during the conduct of its clinical investigations,' concluded Mr. Sellke.
Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not predictions of actual future results. Actual results could differ materially from those anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 1999 Annual Report on Form 10-KSB under the caption ``Risk Factors,' as well as others not now anticipated. These risks and uncertainties include, without limitation, the Company's ability to receive regulatory approval for its CVProfilor(TM) DO-2020 System; the availability of third-party reimbursements; market acceptance of the Company's products; the ability to operate and maintain the Central Data Management Facility (CDMF) on a commercial scale; regulatory restrictions pertaining to data privacy issues in utilizing the CDMF; the ability of third parties to manufacture the Company's products on a commercial scale and in compliance with regulatory requirements; the availability of integral components for the Company's products; the Company's ability to develop distribution channels; increased competition; changes in government regulation; health care reform; exposure to potential product liability; and the Company's ability to protect its proprietary technology. |
